Stay updated on Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.

Latest updates to the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a minor update to the ClinicalTrials.gov study page. This change does not modify any study details or visible content.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedRevision label updated from v3.6.4 to v3.6.5 on the page, indicating a new version of the ClinicalTrials.gov record. This reflects an internal update to the page rather than changes to study details or results.SummaryDifference0.1%

- Check52 days agoChange DetectedThe page's revision tag was updated from v3.6.3 to v3.6.4, signaling a new release of the page template or tooling; there are no visible content changes to the study details.SummaryDifference0.1%

- Check74 days agoChange DetectedThe page’s revision tag changed from v3.6.2 to v3.6.3. This reflects a deployment/version update rather than a change to the page content.SummaryDifference0.1%

- Check81 days agoChange DetectedThe page now shows revision v3.6.2, replacing the previous v3.6.0. This indicates a newer revision of the page content and related materials.SummaryDifference0.1%

- Check95 days agoChange DetectedThe page now includes new guidance sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the recruitment status to No longer looking for participants, indicating no current enrollment. A header formatting change and a revision label update are also present.SummaryDifference0.5%

Stay in the know with updates to Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Gemcitabine in Leiomyosarcoma Clinical Trial page.